Affiliation: Yale University
- Antigen presentation in graft-vs-host diseaseWarren D Shlomchik
Section of Medical Oncology, Yale University School of Medicine, PO Box 208032, 333 Cedar Street, New Haven, CT 06520, USA
Exp Hematol 31:1187-97. 2003
- Graft-versus-host diseaseWarren D Shlomchik
Yale University School of Medicine, sections of Medical Oncology and Immunobiology, PO Box 208032, New Haven, Connecticut 06520, USA
Nat Rev Immunol 7:340-52. 2007..This Review focuses on research in mouse models pursued to achieve this goal...
- Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplantsLoredana Ruggeri
Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
Science 295:2097-100. 2002..NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation...
- Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cellsBritt E Anderson
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
Blood 111:5242-51. 2008..Taken together, these data argue against the hypothesis that T(EM) fail to induce GVHD because of inefficient trafficking to LN and PP...
- Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cellsDaniel H Kaplan
Department of Dermatology, 2Department of Laboratory Medicine, 3Section of Immunobiology, and 4Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
J Exp Med 204:2545-52. 2007..Thus, TGFbeta1 derived from LCs acts directly on LCs through an autocrine/paracrine loop, and it is required for LC development and/or survival...
- Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivityDaniel H Kaplan
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Immunity 23:611-20. 2005..Moreover, we showed that LCs act during the priming and not the effector phase. Thus, LCs not only were dispensable for CHS, but they served to regulate the response, a previously unappreciated function...
- Donor APCs are required for maximal GVHD but not for GVLCatherine C Matte
Section of Medical Oncology, Yale University School of Medicine, PO Box 208032, 333 Cedar Street, New Haven, Connecticut 06520, USA
Nat Med 10:987-92. 2004..These studies identify donor APCs as a new target for treating GVHD, which may preserve GVL...
- Langerhans cells are not required for efficient skin graft rejectionJagdeep S Obhrai
Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA
J Invest Dermatol 128:1950-5. 2008..Thus, LCs in the donor graft are required for long-term skin engraftment, which supports a regulatory role for LCs in skin graft acceptance...
- APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host diseaseYi Zhang
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Immunol 169:7111-8. 2002..Thus, tissue-resident APCs control the local recruitment of allo-reactive donor T cells and the subsequent development of acute GVHD...
- CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVLCatherine Matte-Martone
Section of Medical Oncology, Cancer Center, Yale University School of Medicine, New Haven, CT 06520 8032, USA
Blood 111:3884-92. 2008..Thus, CD4 cells use distinct effector mechanisms in GVHD and GVL: direct cytolytic action is required for GVL but not for GVHD. If these noncytolytic pathways can be inhibited, then GVHD might be ameliorated while preserving GVL...
- Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host diseaseHong Zheng
Penn State Milton S Hershey Medical Center, Department of Medicine, Hershey, PA, USA
Blood 111:2476-84. 2008....
- Memory CD4+ T cells do not induce graft-versus-host diseaseBritt E Anderson
Sections of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
J Clin Invest 112:101-8. 2003..If these murine results are applicable to human alloSCT, selective administration of memory T cells could greatly improve post-transplant immune reconstitution...
- Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killingCatherine C Matte
Yale University School of Medicine, Section of Medical Oncology, PO Box 208032, New Haven, CT 06520, USA
Blood 103:4353-61. 2004..CD4 GVL did not require target Fas expression. These results suggest that CPCML's GVL sensitivity may in part be explained by the minimal requirements for T-cell killing, and GVL-resistance may be related to MHC II expression...
- Transplantation's greatest challenges: advances in chronic graft-versus-host diseaseWarren D Shlomchik
Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
Biol Blood Marrow Transplant 13:2-10. 2007..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy...
- Recipient gammadelta T cells in graft-versus-host diseaseBritt E Anderson
Blood 107:3808-9; author reply 3809. 2006
- Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host diseaseBritt E Anderson
Department of Laboratory Medicine, Yale University School of Medicine, 333 Cedar St, PO Box 208035, New Haven, CT 06520 8035, USA
Blood 104:1565-73. 2004..Additional CD4+CD25+ cells also promoted healing of established lesions, suggesting that their effects persist during the evolution of cGVHD...
- Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organBritt E Anderson
Section of Immunobiology, The Department of Dermatology, Yale University School of Medicine, 333 Cedar St, Box 208035, New Haven, CT 06520 8035, USA
Blood 105:2227-34. 2005..These results identify differences in APC requirements between CD8-mediated aGVHD and CD4-mediated cGVHD. They further highlight donor APCs as additional targets for GVHD therapy...
- Target antigens determine graft-versus-host disease phenotypeDaniel H Kaplan
Departments of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
J Immunol 173:5467-75. 2004..Thus, the selection of immunodominant Ags determines the target and character of GVHD, providing insight into the genetic basis for different forms of GVHD...
- ALLOIMMUNITY TO CML IN A NOVEL MURINE MODELWarren Shlomchik; Fiscal Year: 2002..D. in immunology and was scientific director of the alloBMT program at the University of Michigan. He has launched a new alloBMT program at Penn and is committed to Dr. Shlomchik's development into an independent clinician scientist. ..
- Novel Immunotoxins for Depletion of Dendritic CellsWarren Shlomchik; Fiscal Year: 2005..The goal of our work is to prevent this attack, thereby making this therapy safer and more widely applicable ..